{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:02:58Z","timestamp":1789437778528,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171976"],"award-info":[{"award-number":["82171976"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013102","name":"Shanghai Municipal Youth Science and Technology Star Project","doi-asserted-by":"publisher","award":["Shanghai Municipal Youth Science and Technology Star Project"],"award-info":[{"award-number":["Shanghai Municipal Youth Science and Technology Star Project"]}],"id":[{"id":"10.13039\/501100013102","id-type":"DOI","asserted-by":"publisher"}]},{"name":"hanghai Pujiang Program","award":["21PJD042"],"award-info":[{"award-number":["21PJD042"]}]},{"DOI":"10.13039\/501100013070","name":"Longhua Hospital Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["No. SHDC12023103"],"award-info":[{"award-number":["No. SHDC12023103"]}],"id":[{"id":"10.13039\/501100013070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08179-5","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:53:10Z","timestamp":1789437190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a preoperative 18F-PSMA-1007 PET\/MR prognostic model for predicting biochemical recurrence in prostate cancer: a multicentre study"],"prefix":"10.1007","author":[{"given":"Jiajia","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangxing","family":"Chunyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjing","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-2062","authenticated-orcid":false,"given":"Biao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"5","key":"8179_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(5):479\u2013505.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"8179_CR2","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618\u201329.","journal-title":"Eur Urol"},{"issue":"9","key":"8179_CR3","doi-asserted-by":"publisher","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","volume":"6","author":"UG Falagario","year":"2023","unstructured":"Falagario UG, et al. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy. JAMA Netw Open. 2023;6(9):e2332900.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"8179_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467\u201379.","journal-title":"Eur Urol"},{"key":"8179_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102630","volume":"122","author":"JA Efstathiou","year":"2024","unstructured":"Efstathiou JA, et al. Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer. Cancer Treat Rev. 2024;122:102630.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"8179_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969\u201374.","journal-title":"JAMA"},{"issue":"6","key":"8179_CR7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","volume":"173","author":"MR Cooperberg","year":"2005","unstructured":"Cooperberg MR, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938\u201342.","journal-title":"J Urol"},{"issue":"4","key":"8179_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.eururo.2009.12.003","volume":"57","author":"G Lughezzani","year":"2010","unstructured":"Lughezzani G, et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol. 2010;57(4):562\u20138.","journal-title":"Eur Urol"},{"issue":"2","key":"8179_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.juro.2010.03.144","volume":"184","author":"J Morote","year":"2010","unstructured":"Morote J, et al. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J Urol. 2010;184(2):506\u201311.","journal-title":"J Urol"},{"issue":"5","key":"8179_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.eururo.2016.08.065","volume":"71","author":"JS Brajtbord","year":"2017","unstructured":"Brajtbord JS, Leapman MS, Cooperberg MR. The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies. Eur Urol. 2017;71(5):705\u20139.","journal-title":"Eur Urol"},{"issue":"22","key":"8179_CR11","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1002\/cncr.26169","volume":"117","author":"MR Cooperberg","year":"2011","unstructured":"Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039\u201346.","journal-title":"Cancer"},{"issue":"2","key":"8179_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"issue":"1","key":"8179_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13550-021-00818-2","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, et al. PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. EJNMMI Res. 2021;11(1):76.","journal-title":"EJNMMI Res"},{"issue":"3","key":"8179_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/pros.21241","volume":"71","author":"S Minner","year":"2011","unstructured":"Minner S, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71(3):281\u20138.","journal-title":"Prostate"},{"key":"8179_CR15","doi-asserted-by":"crossref","unstructured":"Mojsak M et al. Application of 18F-PSMA-1007 PET\/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a Prospective Study of 60 Patients with Very Low PSA Levels\u2009\u2264\u20090.5 ng\/mL. Cancers (Basel). 2023;15(16).","DOI":"10.3390\/cancers15164185"},{"issue":"6","key":"8179_CR16","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2967\/jnumed.122.265025","volume":"64","author":"I Sonni","year":"2023","unstructured":"Sonni I, et al. (68)Ga-PSMA PET\/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023;64(6):902\u20139.","journal-title":"J Nucl Med"},{"key":"8179_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-01029-9","author":"Z Jia","year":"2025","unstructured":"Jia Z, et al. Lymph node dissection based on 18F-PSMA PET\/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study. Prostate Cancer Prostatic Dis. 2025. https:\/\/doi.org\/10.1038\/s41391-025-01029-9.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"8179_CR18","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00330-021-08140-0","volume":"32","author":"S Jentjens","year":"2022","unstructured":"Jentjens S, et al. Prospective comparison of simultaneous [(68Ga)]Ga-PSMA-11 PET\/MR versus PET\/CT in patients with biochemically recurrent prostate cancer. Eur Radiol. 2022;32(2):901\u201311.","journal-title":"Eur Radiol"},{"issue":"8","key":"8179_CR19","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.2967\/jnumed.118.221564","volume":"60","author":"IA Burger","year":"2019","unstructured":"Burger IA, et al. (68)Ga-PSMA-11 PET\/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. J Nucl Med. 2019;60(8):1118\u201323.","journal-title":"J Nucl Med"},{"issue":"5","key":"8179_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, et al. Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41(5):887\u201397.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"8179_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.euo.2018.09.010","volume":"2","author":"PJL De Visschere","year":"2019","unstructured":"De Visschere PJL, et al. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. Eur Urol Oncol. 2019;2(1):47\u201376.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"8179_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2967\/jnumed.118.225276","volume":"61","author":"B Kranzb\u00fchler","year":"2020","unstructured":"Kranzb\u00fchler B, et al. Detection Rate and Localization of Prostate Cancer Recurrence Using (68)Ga-PSMA-11 PET\/MRI in Patients with Low PSA Values\u2009\u2264\u20090.5 ng\/mL. J Nucl Med. 2020;61(2):194\u2013201.","journal-title":"J Nucl Med"},{"issue":"4","key":"8179_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8179_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, et al. Detection Efficacy of (18)F-PSMA-1007 PET\/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2019;60(3):362\u20138.","journal-title":"J Nucl Med"},{"issue":"16","key":"8179_CR25","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018;78(16):4786\u20139.","journal-title":"Cancer Res"},{"key":"8179_CR26","doi-asserted-by":"crossref","unstructured":"Kudura K et al. Tumor Segmentation on PSMA PET\/CT Predicts Survival in Biochemical Recurrence of Prostate Cancer: A Retrospective Study Using [(68)Ga]Ga-PSMA-11 and [(18)F]-PSMA-1007. Cancers (Basel). 2025;17(13).","DOI":"10.3390\/cancers17132249"},{"issue":"11","key":"8179_CR27","first-page":"1644","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, et al. The PRIMARY Score: Using Intraprostatic (68)Ga-PSMA PET\/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022;63(11):1644\u201350.","journal-title":"J Nucl Med"},{"issue":"4","key":"8179_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2214\/AJR.18.20498","volume":"212","author":"MH Choi","year":"2019","unstructured":"Choi MH, et al. Prebiopsy biparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2: a multicenter study. AJR Am J Roentgenol. 2019;212(4):839\u201346.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"8179_CR29","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139.","journal-title":"CA Cancer J Clin"},{"key":"8179_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","author":"P Cornford","year":"2024","unstructured":"Cornford P, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"issue":"5","key":"8179_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.eururo.2004.07.010","volume":"46","author":"V Poulakis","year":"2004","unstructured":"Poulakis V, et al. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy. Eur Urol. 2004;46(5):571\u20138.","journal-title":"Eur Urol"},{"issue":"4","key":"8179_CR32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.euo.2022.09.005","volume":"6","author":"M Baboudjian","year":"2023","unstructured":"Baboudjian M, et al. Magnetic Resonance Imaging-based T-staging to predict biochemical recurrence after radical prostatectomy: a step towards the iTNM classification. Eur Urol Oncol. 2023;6(4):406\u201313.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"8179_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.mcna.2010.08.024","volume":"95","author":"CK Gjertson","year":"2011","unstructured":"Gjertson CK, Albertsen PC. Use and assessment of PSA in prostate cancer. Med Clin North Am. 2011;95(1):191\u2013200.","journal-title":"Med Clin North Am"},{"issue":"5","key":"8179_CR34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.pathol.2019.05.001","volume":"51","author":"JR Srigley","year":"2019","unstructured":"Srigley JR, et al. Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology. 2019;51(5):463\u201373.","journal-title":"Pathology"},{"key":"8179_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2026.03.003","author":"Y Ozawa","year":"2026","unstructured":"Ozawa Y, et al. Integrating genomic prostate score with preoperative and postoperative cancer of the prostate risk assessment scores to predict biochemical recurrence after radical prostatectomy. Eur Urol Oncol. 2026. https:\/\/doi.org\/10.1016\/j.euo.2026.03.003.","journal-title":"Eur Urol Oncol"},{"issue":"20","key":"8179_CR36","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1200\/JCO.21.02800","volume":"40","author":"D Tilki","year":"2022","unstructured":"Tilki D, et al. Adjuvant versus early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer and the risk of death. J Clin Oncol. 2022;40(20):2186\u201392.","journal-title":"J Clin Oncol"},{"issue":"10","key":"8179_CR37","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341\u201352.","journal-title":"Lancet Oncol"},{"issue":"11","key":"8179_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","volume":"23","author":"DE Spratt","year":"2025","unstructured":"Spratt DE, et al. Version 3.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(11):469\u201393. Prostate Cancer.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"8179_CR39","first-page":"876","volume":"32","author":"XY Chen","year":"2021","unstructured":"Chen XY, et al. Clinical value of dual-tracer 18F-PSMA and 18F-FDG PET\/MR for preoperative evaluation of prostate cancer. J Chin Clin Med Imaging. 2021;32(12):876\u201383.","journal-title":"J Chin Clin Med Imaging"},{"issue":"10442","key":"8179_CR40","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","volume":"403","author":"CC Parker","year":"2024","unstructured":"Parker CC, et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet. 2024;403(10442):2416\u201325.","journal-title":"Lancet"},{"issue":"6","key":"8179_CR41","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.eururo.2023.06.022","volume":"84","author":"L Dja\u00efleb","year":"2023","unstructured":"Dja\u00efleb L, et al. Presurgical (68)Ga-PSMA-11 positron emission tomography for biochemical recurrence risk assessment: a follow-up analysis of a multicenter prospective phase 3 imaging trial. Eur Urol. 2023;84(6):588\u201396.","journal-title":"Eur Urol"},{"issue":"12","key":"8179_CR42","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.2967\/jnumed.122.263897","volume":"63","author":"F Moradi","year":"2022","unstructured":"Moradi F, et al. (68)Ga-PSMA-11 PET\/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment. J Nucl Med. 2022;63(12):1822\u20138.","journal-title":"J Nucl Med"},{"issue":"13","key":"8179_CR43","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","volume":"48","author":"EG Arnfield","year":"2021","unstructured":"Arnfield EG, et al. Clinical insignificance of [(18)F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging. 2021;48(13):4495\u2013507.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8179_CR44","first-page":"180","volume":"45","author":"HX Chunyu","year":"2025","unstructured":"Chunyu HX, Hu JJ, Li B. Research progress of PSMA PET radiomics in prostate cancer. Chin J Nucl Med Mol Imaging. 2025;45(3):180\u20134.","journal-title":"Chin J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08179-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08179-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08179-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:53:13Z","timestamp":1789437193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08179-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":44,"alternative-id":["8179"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08179-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Approval was granted by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (approval date: July 18, 2024; approval no. 2024\u2009\u2212\u2009244).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided routine clinical consent before undergoing PET\/MR imaging. The requirement for additional study-specific informed consent was waived by the Ethics Committee because of the retrospective, de-identified nature of the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Biao Li is an editor of this journal. The remaining authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}